Peter A. Thompson, a major owner of Nivalis Therapeutics, Inc. and a director of the company, just received 7,650 options from the company. The strike price of the options received was $11.31, and these expire on January 01, 2028. Thompson now owns at least 7,650 options on the company.
Some additional info was provided as follows:
The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
100% of the shares subject to the option become vested and exercisable on January 2, 2019.
In accordance with the internal policies of OrbiMed Advisors LLC, the options received by Dr. Thompson must be held for the benefit of OrbiMed Advisors LLC and its affiliates.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Nivalis Therapeutics, Inc. makes a similar move, sign up!